ES2173863T3 - Derivados de analogos amida de ciertas quinolizinas con puentes de metano. - Google Patents

Derivados de analogos amida de ciertas quinolizinas con puentes de metano.

Info

Publication number
ES2173863T3
ES2173863T3 ES92401618T ES92401618T ES2173863T3 ES 2173863 T3 ES2173863 T3 ES 2173863T3 ES 92401618 T ES92401618 T ES 92401618T ES 92401618 T ES92401618 T ES 92401618T ES 2173863 T3 ES2173863 T3 ES 2173863T3
Authority
ES
Spain
Prior art keywords
chem
treatment
derivatives
quinolizinas
amida
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92401618T
Other languages
English (en)
Inventor
Maurice W Gittos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2173863T3 publication Critical patent/ES2173863T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS DERIVADOS DEL AMIDO DE COMPUESTOS DEL TIPO 2, 6-METANO-2H-QUINOLICINA, A NUEVOS PRODUCTOS INTERMEDIOS Y A UN PROCESO PARA SU PREPARACION, A SU CAPACIDAD DE INDUCIR UN BLOQUEO DE LOS RECEPTORES 5HTSUB 3 Y A SU APLICACION DE USO FINAL EN EL TRATAMIENTO DE LAS NAUSEAS Y EL VOMITO INDUCIDO QUIMIOTERAPICAMENTE, COMO AGENTES ANTIANSIEDAD, EN EL TRATAMIENTO SINTOMATICO DEL DOLOR ASOCIADO CON LA MIGRAÑA, COMO AGENTES ANTIARRITMICOS, EN EL TRATAMIENTO DE DESORDENES DEL CONOCIMIENTO, EN EL TRATAMIENTO DE LA PSICOSIS ENDOGENA ALUCINATORIA DEL TIPO QUE SE MANIFIESTA EN PACIENTES QUE SUFREN DE ESQUIZOFRENIA, Y MANIA, EN EL TRATAMIENTO DEL GLAUCOMA, PARA ESTIMULAR LA MOTILIDAD GASTRICA, PARA COMBATIR EL ABUSO DE LAS DROGAS, PARA TRATAR LA AMNEA DEL SUEÑO Y PARA TRATAR EL SINDROME DE COLON IRRITABLE.
ES92401618T 1991-06-11 1992-06-11 Derivados de analogos amida de ciertas quinolizinas con puentes de metano. Expired - Lifetime ES2173863T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91401550A EP0517984A1 (en) 1991-06-11 1991-06-11 Derivatives of amide analogs of certain methano bridged quinolizines

Publications (1)

Publication Number Publication Date
ES2173863T3 true ES2173863T3 (es) 2002-11-01

Family

ID=8208580

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92401618T Expired - Lifetime ES2173863T3 (es) 1991-06-11 1992-06-11 Derivados de analogos amida de ciertas quinolizinas con puentes de metano.

Country Status (16)

Country Link
EP (2) EP0517984A1 (es)
JP (1) JP3377227B2 (es)
KR (1) KR100234926B1 (es)
AT (1) ATE214392T1 (es)
AU (1) AU649836B2 (es)
CA (1) CA2070573C (es)
DE (1) DE69232473T2 (es)
DK (1) DK0518767T3 (es)
ES (1) ES2173863T3 (es)
FI (1) FI112866B (es)
HU (1) HU212735B (es)
IE (1) IE921874A1 (es)
IL (1) IL102132A (es)
NO (1) NO305124B1 (es)
NZ (1) NZ243031A (es)
PT (1) PT518767E (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508287A (en) * 1992-02-24 1996-04-16 Merrell Pharmaceuticals Inc. 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
KR100287933B1 (ko) * 1992-02-24 2001-05-02 슈테펜엘.네스비트 5-ht3-수용체 길항제로서의 2,6-메타노-2h-퀴놀리진 유도체,이의 제조방법 및 이를 포함하는 약제학적 조성물
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
PT1030667E (pt) 1997-11-14 2005-06-30 Akzo Nobel Nv Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
PT1066036E (pt) 1998-02-27 2006-09-29 Univ Illinois Agentes com actividade relacionada com serotonina para o tratamento da apneia do sono
US7160898B2 (en) 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
EP1833467B1 (en) 2004-12-20 2016-08-03 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
US7608714B2 (en) * 2006-01-05 2009-10-27 TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság Production of dolasetron
CN101774971B (zh) * 2010-02-10 2011-07-27 山东众诚药业股份有限公司 高纯度1-甲基吲唑-3-羧酸的生产方法
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB219363A (en) * 1923-03-24 1924-07-24 Abraham Preston Improvements in or in connection with bed couches
EP0498466B1 (en) * 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
EP0330788A1 (en) * 1988-03-01 1989-09-06 Merrell Dow Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
IL102132A0 (en) 1993-01-14
FI922695A0 (fi) 1992-06-10
DE69232473T2 (de) 2002-11-21
IL102132A (en) 1996-10-31
NO305124B1 (no) 1999-04-06
ATE214392T1 (de) 2002-03-15
EP0518767A2 (en) 1992-12-16
HU9201939D0 (en) 1992-08-28
AU1803792A (en) 1992-12-24
DK0518767T3 (da) 2002-07-01
EP0518767A3 (en) 1993-05-05
FI112866B (fi) 2004-01-30
KR100234926B1 (ko) 1999-12-15
NO922270D0 (no) 1992-06-10
JPH05202044A (ja) 1993-08-10
KR930000518A (ko) 1993-01-15
DE69232473D1 (de) 2002-04-18
FI922695A (fi) 1992-12-12
HU212735B (en) 1996-10-28
NZ243031A (en) 1994-02-25
NO922270L (no) 1992-12-14
JP3377227B2 (ja) 2003-02-17
EP0517984A1 (en) 1992-12-16
CA2070573C (en) 2003-04-15
CA2070573A1 (en) 1992-12-12
HUT61549A (en) 1993-01-28
EP0518767B1 (en) 2002-03-13
AU649836B2 (en) 1994-06-02
IE921874A1 (en) 1992-12-16
PT518767E (pt) 2002-09-30

Similar Documents

Publication Publication Date Title
ES2173863T3 (es) Derivados de analogos amida de ciertas quinolizinas con puentes de metano.
FI101223B1 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 6-substituoitujen tai 2-alkyylisubstituoitujen indoli- tai 2,3-dihydroindolijohdannaisten valmistamiseksi
NZ319169A (en) Imidazole derivatives as <alpha>-2 agonists
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
NZ238956A (en) 3-arylindole or 3-arylindazole derivatives and medicaments thereof.
ATE63744T1 (de) 3-amino-dihydro-(1>-benzopyrane und benzothiopyrane.
DE69230498D1 (de) 2-Pyrazinylethylamin-Derivate und ihre Verwendung als Arzneimittel.
ES2111326T3 (es) Derivados de imidazolona y oxazolona como antagonistas de dopamina.
AP9801410A0 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists.
DE3666430D1 (en) Condensed seven-membered heterocyclic compounds, their production and use
ATE108444T1 (de) 3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik.
TH13495A (th) อนุพันธ์ไซโคลเฮกเซน และเตตราไฮโดรไพราน

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 518767

Country of ref document: ES